Corpus ID: 4987180

Delivering on the value proposition of precision medicine: the view from healthcare payers.

@article{Kogan2018DeliveringOT,
  title={Delivering on the value proposition of precision medicine: the view from healthcare payers.},
  author={J. Kogan and P. Empey and Justin Kanter and D. Keyser and W. Shrank},
  journal={The American journal of managed care},
  year={2018},
  volume={24 4},
  pages={
          177-179
        }
}
A long-held assumption and expectation has been that genomics-based precision medicine will provide clinicians with the tools and therapies they need to consistently deliver the right treatment to the right patient while simultaneously reducing waste and yielding cost savings for health systems. The pace of discovery within the field of precision medicine has been remarkable, yet optimal uptake of new genetic tests and genetically targeted therapies will occur only if payers recognize their… Expand
3 Citations
Value Creation in Precision Medicine: Acknowledging the Need to Devise New Ways to Measure. The Value of Healthcare
TLDR
In this article, Porter advocates that considering patients as the main stakeholder of healthcare will improve value for all stakeholders, and provides suggestions on how to implement value-based healthcare. Expand
Biomarker imprecision in precision medicine
  • K. Pritzker
  • Medicine
  • Expert review of molecular diagnostics
  • 2018
TLDR
Precision medicine is a conceptual model for disease taxonomy that extends the long-established clinical pathologic correlation disease model to include and emphasize genetics, genomics, and systems biology knowledge and is predicated on ideas that application of the vast amount of genomics and other biochemical data generated by life sciences research over the past 60 years can yield more precise diagnostics and therapies. Expand
Plasma PIK3CA Mutation Testing in Advanced Breast Cancer Patients for Personalized Medicine: A Value Proposition.
TLDR
It was evident that robust clinical evidence exists to support the role of ctDNA PIK3CA mutation evaluation in identifying patients with advanced breast cancer who could benefit from PI3Ki treatment. Expand

References

SHOWING 1-7 OF 7 REFERENCES
Specialty medications: traditional and novel tools can address rising spending on these costly drugs.
TLDR
The evolution of the specialty market is described, the current state of specialty medication use is characterized, key challenges and potential solutions are articulated, and collaborative efforts to reduce waste and promote value are articulated. Expand
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy
TLDR
All studies in the present review focused on selecting antiplatelet agents for carriers of CYP2C19 LOF allele(s) and cost-effectiveness of genotype-guided use of antiplatelets was demonstrated in high-risk ACS patients. Expand
Health Insurers Struggle to Manage Number, Cost of Genetic Tests.
said to have an allele labeled as *2, shown on the test report as CYP2C19*2. No one in the doctor’s office— including the doctor himself—knew the significance of the asterisk. “The doctor called meExpand
Pharmacogenomics to achieve precision medicine.
  • P. Empey
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2016
The term precision medicine was thrust into the national lexicon in early 2015 with the launch of the Precision Medicine Initiative by President Obama in his State of the Union Address. The missionExpand
Cytochrome p-450 polymorphisms and response to clopidogrel.
TLDR
Carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers. Expand